Tag: form

SURFSIDE BEACH, S.C., Aug. 15, 2025 (GLOBE NEWSWIRE) -- RealESALetter.com is excited to announce its nationwide service that makes getting an emotional support animal letter easier than ever. People across America can now skip the stressful paperwork and long waits and instead get a fully legitimate ESA letter from the comfort of their home in as little as 24 hours.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CS Disco (LAW) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options

VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ("VERSES" or the "Company"), a cognitive computing company pioneering next-generation agentic software systems today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months ended June 30, 2025, with the U.S. Securities and Exchange Commission (“SEC”).

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Starbucks (SBUX) To Contact Him Directly To Discuss Their Options

SUFFOLK, Va. and HAMPTON, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Hampton Roads based TowneBank (NASDAQ: TOWN) and Old Point Financial Corporation (NASDAQCM: OPOF) (“Old Point”), the parent company of The Old Point National Bank of Phoebus (“Old Point National Bank”), today announced that they had received regulatory approval from the Federal Deposit Insurance Corporation (the “FDIC”) and the Bureau of Financial Institutions of the Virginia State Corporation Commission to complete the proposed merger of Old Point and Old Point National Bank with TowneBank. All regulatory approvals required for the transaction have now been received. The merger is expected to close on or about September 1, 2025, subject to the satisfaction of customary closing conditions.

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH